|[February 10, 2014]
e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers
OXFORD & NEWCASTLE, England --(Business Wire)--
e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first
healthy volunteer in a newly initiated Phase I clinical trial with an
oral formulation of its anti-cancer compound, ETS2101.
The Phase I study will employ escalating doses of ETS2101 given orally
in healthy subjects to evaluate the pharmacokinetics (PK) and oral
bioavailability of ETS2101 in this form. The trial, which is conducted
in the UK, is expected to recruit 24 healthy volunteers and is
anticipated to complete in Q4 2014.
Stephen Self, e-Therapeutics' Development Director, said: "We are
pleased to be broadening our investigations of ETS2101 by starting a
Phase I trial with an oral formulation. This may be an additional
delivery route for patients. We will be able to cross-refer results with
this oral formulation to the afety, dosing and activity data on ETS2101
from the two existing Phase I studies with the intravenous (I.V.)
formulation of ETS2101."
An I.V. formulation of ETS2101 is in two Phase I studies, an
investigator-led study in brain cancer at the Moores Cancer Center of
the University of California San Diego and a study at three UK Centers
that is focused on patients with a variety of solid tumours.
ETS2101 (dexanabinol) is a synthetic cannabinoid identified by
e-Therapeutics' network pharmacology as a drug with potential in cancer
treatment. Preclinical studies provided evidence of activity in a wide
variety of cancer cell lines. Two phase I studies of ETS2101 are
ongoing, one in patients with primary or secondary brain cancers and one
in patients with various advanced solid tumours.
e-Therapeutics is an AIM-listed biotechnology company with a proprietary
platform in network pharmacology, an innovative new approach to drug
discovery based on advances in network science and chemical biology. The
Company's discovery and development activity is focused in cancer and
disorders of the nervous system. e-Therapeutics is based at sites in
Oxford and Newcastle, UK. For more information about the Company please
[ Back To Technology News's Homepage ]